Publication date: Jul 10, 2025
People living with human immunodeficiency virus type 1 (PLWH) are at increased risk for severe outcomes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although SARS-CoV-2 mRNA vaccines have demonstrated strong immunogenicity in general populations, comparative data regarding the humoral immune responses in PLWH remain limited. This study aimed to compare the humoral responses elicited by two widely used mRNA vaccines, BNT162b2 and mRNA-1273, in Japanese PLWH. This observational study investigated 119 PLWH without prior SARS-CoV-2 infection who received two doses of BNT162b2 (n = 91) or mRNA-1273 (n = 28). Anti-SARS-CoV-2 spike antibody titers were measured at three time points: before vaccination and approximately 6 weeks and 24 weeks after the second vaccine dose. Factors associated with the antibody responses were analyzed by multivariate logistic regression. Both vaccines elicited robust antibody responses in PLWH, with the mRNA-1273 group having significantly higher antibody titers than the BNT162b2 group at 6 and 24 weeks (P
| Concepts | Keywords |
|---|---|
| 6weeks | BNT162b2 |
| Hiv | HIV-1 |
| Japanese | Humoral immunity |
| Mrna | Immunocompromised host |
| Severe | mRNA-1273 |
| SARS-CoV-2 vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | infection |
| disease | MESH | SARS-CoV-2 infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | Immunocompromised host |